Stock Comparison

JNJ vs MBOT

Johnson & Johnson vs Microbot Medical Inc

The Verdict

MBOT takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

MBOT

Microbot Medical Inc

7.2

out of 10

Solid Pick

Head-to-Head

$557.1B

Market Cap

$136M

26.5

P/E Ratio

2.0

21.8%

Profit Margin

-3496.2%

26.3%

Return on Equity

-21.8%

0.6

Debt-to-Equity

N/A

Conservative

Overall Risk

Aggressive

1.0

DVR Score

7.2

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

MBOT7.2/10

Microbot Medical remains a high-risk, high-reward proposition with compelling 10x potential in the robotic endovascular surgery market. The significant milestone of reporting first LIBERTY commercial revenue in Q1 2026, coupled with the transition to Full Market Release and recent regulatory approval in Israel, marks substantial progress in validating its strategic vision and technology. These dev...

Full MBOT Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.